Genix Financial Statements From 2010 to 2025
| GENPF Stock | USD 0.03 0.00 0.00% |
Check Genix Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Genix Pharmaceuticals' main balance sheet or income statement drivers, such as , as well as many indicators such as . Genix financial statements analysis is a perfect complement when working with Genix Pharmaceuticals Valuation or Volatility modules.
Genix |
Genix Pharmaceuticals Company Current Valuation Analysis
Genix Pharmaceuticals' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Genix Pharmaceuticals Current Valuation | 3.14 M |
Most of Genix Pharmaceuticals' fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Genix Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Genix Pharmaceuticals has a Current Valuation of 3.14 M. This is 99.98% lower than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—Specialty & Generic industry. The current valuation for all United States stocks is 99.98% higher than that of the company.
Genix Pharmaceuticals Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Genix Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Genix Pharmaceuticals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Genix Pharmaceuticals competition to find correlations between indicators driving Genix Pharmaceuticals's intrinsic value. More Info.Genix Pharmaceuticals is rated # 2 in return on equity category among its peers. It is rated # 4 in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Genix Pharmaceuticals' earnings, one of the primary drivers of an investment's value.About Genix Pharmaceuticals Financial Statements
Genix Pharmaceuticals stakeholders use historical fundamental indicators, such as Genix Pharmaceuticals' revenue or net income, to determine how well the company is positioned to perform in the future. Although Genix Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. For example, changes in Genix Pharmaceuticals' assets and liabilities are reflected in the revenues and expenses on Genix Pharmaceuticals' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Genix Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Genix Pharmaceuticals Corporation formulates, manufactures, licenses, and markets life sciences related products with focus on nutraceuticals and pharmaceuticals in Canada. Genix Pharmaceuticals Corporation was incorporated in 1993 and is based in Vancouver, Canada. Genix Pharmaceuticals is traded on OTC Exchange in the United States.
Currently Active Assets on Macroaxis
| DD | Dupont De Nemours | |
| CRDO | Credo Technology Group | |
| GOOG | Alphabet Inc Class C | |
| BAC | Bank of America | |
| CRM | Salesforce |
Other Information on Investing in Genix Pink Sheet
Genix Pharmaceuticals financial ratios help investors to determine whether Genix Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Genix with respect to the benefits of owning Genix Pharmaceuticals security.